FY2025 · ended Dec 31, 2025 · Revenue $4.30B, +10.4% YoY · Filed Feb 20, 2026
Idexx Laboratories Inc /DE (IDXX) files with the SEC under industry code 2835, In Vitro & In Vivo Diagnostic Substances. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $4.3 billion and net income of $1.1 billion. Free cash flow was $1.1 billion. As of Sep 30, 2026 it held $197.5 million in cash and investments and $499.0 million in total debt.
Revenue (TTM)
$4.66B
+11.9% vs year-ago TTM
Net income (TTM)
$1.18B
+15.1% vs year-ago TTM
Operating cash flow (TTM)
$1.42B
+30.4% vs year-ago TTM
Free cash flow (TTM)
$1.30B
+35.3% vs year-ago TTM
EPS (TTM)
$14.82
+17.6% vs year-ago TTM
Dividend per share
None
Shares outstanding
79.62M
-2.1% vs prior year
Net cash
$-301.43M
as of Sep 30, 2026
Operating margin
32.3%
FY 2026
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- IDXX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Westbrook, ME
- SEC filer status
- Large accelerated filer
- SEC CIK
- 874716
Other In Vitro & In Vivo Diagnostic Substances companies
- Lantheus Holdings, Inc. LNTH
- Neogen Corp NEOG
- Celldex Therapeutics, Inc. CLDX
- Intellia Therapeutics, Inc. NTLA
- QuidelOrtho Corp QDEL
- Achieve Life Sciences, Inc. ACHV
- Myriad Genetics Inc MYGN
- Alpha Teknova, Inc. TKNO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $4.3B | $3.9B | $3.7B | $3.4B | $3.2B |
| Operating income | $1.4B | $1.1B | $1.1B | $898.8M | $932.0M |
| Net income | $1.1B | $887.9M | $845.0M | $679.1M | $744.8M |
| Diluted EPS | $13.08 | $10.67 | $10.06 | $8.03 | $8.60 |
| Operating cash flow | $1.2B | $929.0M | $906.5M | $543.0M | $755.5M |
| Free cash flow | $1.1B | $808.1M | $772.9M | $394.1M | $636.0M |
| Total assets | $3.4B | $3.3B | $3.3B | $2.7B | $2.4B |
| Total liabilities | $1.7B | $1.7B | $1.8B | $2.1B | $1.7B |
| Stockholders' equity | $1.6B | $1.6B | $1.5B | $608.7M | $690.0M |
| Cash and investments | $180.1M | $288.3M | $453.9M | $112.5M | $144.5M |
| Total debt | $578.2M | $737.2M | $817.7M | $891.4M | $958.0M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 2, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 2, 2026 | Nov 2, 2026 |
| 10-Q | Quarterly report | Aug 4, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 4, 2026 | Aug 4, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change, Shareholder vote results
|
May 15, 2026 | May 12, 2026 |
| 10-Q | Quarterly report | May 5, 2026 | Mar 31, 2026 |
All 1005 Idexx Laboratories Inc /DE SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.